H.C. Wainwright raised the firm’s price target on Revolution Medicines (RVMD) to $72 from $64 and keeps a Buy rating on the shares. The analyst believes the RMC-6236 Phase 1 data “risk-mitigate” the ongoing RASolute 302 trial and planned RASolve 301 trial. It is encouraged by the initial combination results.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines 14.13M share Secondary priced at $46.00
- Revolution Medicines price target raised to $87 from $82 at Guggenheim
- Revolution Medicines price target raised to $71 from $63 at JPMorgan
- Revolution Medicines announces $600M common stock offering
- Revolution Medicines price target raised to $80 from $70 at Stifel